Cargando…
Biologic targeting in the treatment of inflammatory bowel diseases
The etiology of inflammatory bowel disease (IBD) has not yet been clarified and immunosuppressive agents which nonspecifically reduce inflammation and immunity have been used in the conventional therapies for IBD. Evidence indicates that a dysregulation of mucosal immunity in the gut of IBD causes a...
Autores principales: | Bosani, Matteo, Ardizzone, Sandro, Porro, Gabriele Bianchi |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726060/ https://www.ncbi.nlm.nih.gov/pubmed/19707398 |
Ejemplares similares
-
Adalimumab for the treatment of Crohn’s disease
por: Cassinotti, Andrea, et al.
Publicado: (2008) -
Certolizumab pegol: an evidence-based review of its place in the treatment of Crohn’s disease
por: Cassinotti, Andrea, et al.
Publicado: (2007) -
Therapeutic Management of Adults with Inflammatory Bowel Disease and Malignancies: A Clinical Challenge
por: Ferretti, Francesca, et al.
Publicado: (2023) -
Dermatological Manifestations in Inflammatory Bowel Diseases
por: Antonelli, Elisabetta, et al.
Publicado: (2021) -
Inflammatory Bowel Disease: Updates on Molecular Targets for Biologics
por: Katsanos, Konstantinos H., et al.
Publicado: (2017)